BridgeMD
New treatment option for Hemangioblastoma of CNS
Official title Propranolol and Von Hippel-Lindau Disease
ClinicalTrials.gov ID: NCT05424016
What this study is testing
What is Propranolol?
Propranolol is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for hemangioblastoma of cns.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Propranolol (beta-blocker), is successfully used for the treatment of infantile hemangiomas, the most common vascular tumor of newborns. The mechanism is related to its anti-angiogenetic and pro-apoptotic effects.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18
- VHL patient with one or more hemangioblastomas of the central nervous system, none of which require urgent surgery (within 3 months)
- Patient with written consent to participate in the study
- Enrolled in a social security plan or beneficiary
You likely can't join if
- Contraindication to the use of propranolol:
- chronic obstructive pulmonary disease and asthma,
- uncontrolled heart failure,
- 2nd and 3rd degree atrioventricular blocks,
- bradycardia (\<50 beats/minute after 3 minutes of rest),
- Raynaud's phenomenon and peripheral arterial disorders,
See the full eligibility criteria
- Age ≥ 18
- VHL patient with one or more hemangioblastomas of the central nervous system, none of which require urgent surgery (within 3 months)
- Patient with written consent to participate in the study
- Enrolled in a social security plan or beneficiary
- Contraindication to the use of propranolol:
- chronic obstructive pulmonary disease and asthma,
- uncontrolled heart failure,
- 2nd and 3rd degree atrioventricular blocks,
- bradycardia (\<50 beats/minute after 3 minutes of rest),
- Raynaud's phenomenon and peripheral arterial disorders,
- arterial hypotension,
- hypersensitivity to propranolol
- cardiogenic shock,
- Prinzmetal's angina,
- sinus disease (including sino-auricular block)
- untreated pheochromocytoma,
- history of anaphylactic reaction,
- in the context of primary and secondary prevention of digestive bleeding in cirrhotics: advanced liver failure with hyperbilirubinemia, massive ascites, hepatic encephalopathy
- predisposition to hypoglycemia (as after fasting or in case of abnormal response to hypoglycemia)
- metabolic acidosis
- Contraindication to MRI:
- claustrophobia,
- presence of a pace maker and other stimulators/implants
- ocular metallic foreign bodies,
- heart valves or ferromagnetic metal vascular clips
- Patients already on Propranolol or other beta blockers
- Patients under guardianship or conservatorship
- Pregnant or breastfeeding women - Woman with a medium-term pregnancy project
The study team makes the final eligibility decision.
Where it's taking place
- Le Kremlin-Bicêtre, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Le Kremlin-Bicêtre, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.